Contineum Therapeutics/$CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Ticker
$CTNM
Sector
Primary listing
Employees
51
Headquarters
Website
CTNM Metrics
BasicAdvanced
$502M
-
-$2.17
-
-
Price and volume
Market cap
$502M
52-week high
$16.33
52-week low
$3.35
Average daily volume
318K
Financial strength
Current ratio
27.496
Quick ratio
26.98
Long term debt to equity
2.264
Total debt to equity
3.161
Profitability
EBITDA (TTM)
-67.736
Management effectiveness
Return on assets (TTM)
-17.38%
Return on equity (TTM)
-26.13%
Valuation
Price to book
1.92
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-6.703
Free cash flow yield (TTM)
-14.92%
Free cash flow per share (TTM)
-2.005
Growth
Earnings per share change (TTM)
-0.84%
3-year earnings per share growth (CAGR)
-41.50%
What the Analysts think about CTNM
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
CTNM Financial Performance
Revenues and expenses
CTNM Earnings Performance
Company profitability
CTNM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Contineum Therapeutics stock?
Contineum Therapeutics (CTNM) has a market cap of $502M as of April 08, 2026.
What is the P/E ratio for Contineum Therapeutics stock?
The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of April 08, 2026.
Does Contineum Therapeutics stock pay dividends?
No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of April 08, 2026.
When is the next Contineum Therapeutics dividend payment date?
Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Contineum Therapeutics?
Contineum Therapeutics (CTNM) does not currently have a Beta indicator.